Comments from the Editors
HEPATOLOGY: A home for hepatocellular cancer publications
Editorial
Alternative pathway therapy for hyperammonemia in liver failure
Viral Hepatitis
Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development
PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression
Mutations in the hepatitis C virus polymerase that increase RNA binding can confer resistance to cyclosporine A
Human immunodeficiency virus and hepatitis C infections induce distinct immunologic imprints in peripheral mononuclear cells
Liver Biology/Pathogiology
Hepatic recruitment of the inflammatory Gr1+ monocyte subset upon liver injury promotes hepatic fibrosis
Steatohepatitis/Metabolic Liver Disease
Nutritional model of steatohepatitis and metabolic syndrome in the Ossabaw miniature swine
Independent effects of physical activity in patients with nonalcoholic fatty liver disease
Apolipoprotein B100 acts as a molecular link between lipid-induced endoplasmic reticulum stress and hepatic insulin resistance
Inhibiting glycosphingolipid synthesis ameliorates hepatic steatosis in obese mice
HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity
Hepatobiliary Malignancies
Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma
MicroRNA-195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells
Chromodomain helicase/adenosine triphosphatase DNA binding protein 1-like (CHD1l) gene suppresses the nucleus-to-mitochondria translocation of nur77 to sustain hepatocellular carcinoma cell survival
Autoimmune, Cholestatic and Biliary Disease
Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells
Bile salt-phospholipid conjugate ursodeoxycholyl lysophosphatidylethanolamide as a hepatoprotective agent
Liver Failure/Cirrhosis/Portal Hypertension
L-ornithine and phenylacetate synergistically produce sustained reduction in ammonia and brain water in cirrhotic rats
L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure
Association between dietary nutrient composition and the incidence of cirrhosis or liver cancer in the united states population
CCR2 promotes hepatic fibrosis in mice
Liver Injury/Regeneration
Toll-like receptor 3 signaling attenuates liver regeneration
p21 is required for dextrose-mediated inhibition of mouse liver regeneration
Hepatobiliary Malignanices
S6K1 deficiency protects against apoptosis in hepatocytes
Liver Biology/Pathobiology
The etiology of liver damage imparts cytokines transforming growth factor 1 or interleukin-13 as driving forces in fibrogenesis
Diferentially expressed adenylyl cyclase isoforms mediate secretory functions in cholangiocyte subpopulation
Hypoxia-inducible factor 1 is up-regulated by oncostatin M and participates in oncostatin M signaling
Single nucleotide polymorphism-mediated translational suppression of endoplasmic reticulum mannosidase I modifies the onset of end-stage liver disease in alpha1-antitrypsin deficiency
Protein or amino acid deprivation differentially regulates the hepatic forkhead box protein A (FOXA) genes through an activating transcription factor-4-independent pathway
AASLD Practice Guidelines
Primary biliary cirrhosis
AASLD Public Policy
Health disparities in liver disease: Time to take notice and take action
Image of the Month
Albinism, cyclic neutropenia, and ceroid pigment in the liver
Hepatology Elsewhere
Things that go BMP in the liver: Bone morphogenetic protein 6 and the control of body iron homeostasis
Correspondence
Mesenchymal origin of hepatic stellate cells, submesothelial cells, and perivascular mesenchymal cells during mouse liver development
Reply
Orlistat for overweight subjects with nonalcoholic steatohepatitis
Diagnosis, management, and treatment of hepatitis C
Management of patients with hepatitis C virus genotype 2 or 3: Comments on updated american association for the study of liver diseases practice guidelines
Comment on the updated AASLD practice guidelines for the diagnosis, management, and treatment of hepatitis C: Treating active drug users
Serum Golgi Phosphoprotein 2 level: A better marker than alpha-fetoprotein for diagnosing early hepatocellular carcinoma
Alpha-fetoprotein and serum golgi phosphoprotein 2 are equally discriminative in detecting early hepatocellular carcinomas
Adipocytokine levels in nonalcoholic fatty liver disease
Utility of magnetic resonance imaging in the evaluation of hepatic fat content
Screening for Wilson's disease in acute liver failure: A comparison of currently available diagnostic tests
Interleukin-17-targeted treatment of alcoholic liver disease
Corrections
Correction